Dados do Trabalho


Identification of new predictive targets with translational potential for canine and human prostatic carcinoma


The prostate is an organ prone to diseases of human aging and benign and malignant prostatic disorders are among the most common diseases that affect men. There are a wide variety of treatment options for the diagnosis of prostate cancer in humans, depending on the risk category in which the disease falls. The dog is the only mammal, besides man, that spontaneously develops canine prostatic hyperplasia (PH), prostatic atrophy and prostatic carcinoma (CaP), associated with age, androgenic hormones, in addition to pre-neoplastic lesions, however, in contrast to CaP in humans, CaP in dogs is not androgen dependent, so androgen deprivation therapy is not effective, thus developing castration-resistant prostatic carcinoma (CRPC). Many treatment modalities used in usual human PCa cannot be applied in CRPC. And in relation to dogs, unfortunately, there is still no effective therapy for the treatment of these tumors, where available pharmacological treatments are scarce, based summarily on the prescription of anti-inflammatory drugs, with a low degree of survival.


Thus, we aim to carry out new translational studies on human and canine PCa, aiming to identify predictive markers and potential common therapeutic targets, to later elucidate the antitumor effect of existing drugs and aiming at the development of targeted therapies.


Sixteen animals were allocated in this study, corresponding to 3 animals in the control group and 13 animals in the neoplasia group. The first analysis performed was the extraction of proteomics data and, subsequently, an integrated analysis to identify interactions between groups. Subsequently, a cross-validation of the data was performed with independent data obtained from the database of canine and human prostatic carcinomas. For the identification of differentially expressed proteins between the experimental groups, biological triplicates were used. Results were compared using Student's t test. Different values were considered with p<0.05 and expression change greater than 1.5 times.


A total of 44 proteins were identified in the performed analyses. Among them, Vimentin and Peptidase proteins showed a significant increase in the neoplasia group when compared to the control group.


A possible increase in the secretion of Vimentin and Peptidase S1 proteins was identified in the neoplasia group when compared to the control group, signaling possible tumor biomarkers. Both proteins show a positive relation with tumor progression and development in both species.


Biomarkers, prostate, cancer

Financiador do resumo

CAPES (88887.701500/2022-00)
FAPESP (2022/00593-0)


Estudo Clínico - Tumores Urológicos